News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Release: First Phase III Data on Innovative Compound for Solid Organ Transplantation To be Featured at American Transplant Congress


5/28/2009 1:18:23 PM

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an investigational co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of nine company-sponsored clinical presentations at the upcoming American Transplant Congress to be held May 30 to June 3 in Boston. Belatacept is in phase III development.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES